Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 563-570

  Cowburn, Peter J ^a,b   Cleland, John G F ^a,b   McArthur, John D ^b   MacLean, Margaret R ^a   Dargie, Henry J ^a,b   McMurray, John J V ^a,b   Morton, James J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Endothelin; Heart failure; Left ventricular dysfunction

Indexed keywords

ENDOTHELIN 1;

ADULT; AGED; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

AGED; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NITROPRUSSIDE; PULMONARY ARTERY; REGIONAL BLOOD FLOW; ULTRASONOGRAPHY, INTERVENTIONAL; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032167507     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00084-4     Document Type: Article

References (38)

1. Yanagisawa M., Kurihara H., Kimura S.et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
2. Furchgott R.F., Vanhoute P.N. Endothelium-derived relaxing and contracting factors. FASEB J. 3:1989;2007-2018.
3. Inoue A., Yanagisawa M., Kimura S.et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 86:1989;2863-2867.
4. Xu D., Emoto N., Giaid A.et al. ECE-1: a membrane bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 78:1994;473-485.
5. Arai H., Hori S., Arimori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 348:1990;730-732.
6. Sakurai T., Yanagisawa M., Takuwa Y.et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature. 348:1990;732-735.
7. Haynes W.G., Webb D.J. Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci. 84:1993;427-433.
8. Hiroe M., Hirata Y., Fujita N.et al. Plasma endothelin levels in idiopathic dilated cardiomyopathy. Am J Cardiol. 68:1991;1114-1115.
9. McMurray J.J., Ray S.G., Abdullah I., Dargie H.J., Morton J.J. Plasma endothelin in chronic heart failure. Circulation. 85:1992;1374-1379.
10. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
11. Stewart D.J., Cernacek P., Costello K.B., Rouleau J.L. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 85:1992;510-517.
12. Wei C.M., Lerman A., Rodeheffer R.J.et al. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
13. Good J.M., Nihoyannopoulos P., Ghatei M.A.et al. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J. 15:1994;1634-1640.
14. Love M.P., McMurray J.J.V. Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res. 31:1996;665-674.
15. Pacher R., BerglerKlein J., Globits S.et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 71:1993;1293-1299.
16. Cacoub P., Dorent R., Nataf P.et al. Plasma endothelin and pulmonary pressures in patients with congestive heart failure. Am Heart J. 126:1993;1484-1488.
17. Tsutamoto T., Wada A., Maeda Y., Adachi T., Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 23:1994;1427-1433.
18. Kiowski W., Sutsch G., Hunziker P.et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
19. Grossman W, McLaurin LP. Clinical measurement of vascular resistance and assessment of vasodilator drugs. In: Grossman W, editor. Cardiac catheterisation and angiography. Philadelphia: Lea and Fabiger, 1980:116-123.
20. Cooper C.J., Landzberg M.J., Anderson T.J.et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation. 93:1996;266-271.
21. Doucette J.W., Cord P.D., Payne H.M.et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 85:1992;1899-1911.
22. Labovitz A.J., Anthonis D.M., Cravens T.L., Kern M.J. Validation of volumetric flow measurements by means of a Doppler-tipped coronary angioplasty guide wire. Am Heart J. 126:1993;1456-1461.
23. Wagner O.F., Vierhapper H., Gasic S., Nowotny P., Waldhausl W. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest. 22:1992;277-282.
24. Weitzberg E., Ahlborg G., Lundberg J.M. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin Physiol. 13:1993;653-662.
25. Kiely D.G., Cargill R.I., Struthers A.D., Lipworth B.J. Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res. 33:1997;378-386.
26. Sutsch G., Bertel O., Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther. 10:1997;717-725.
27. McCulloch K.M., Docherty C.C., Morecroft I., MacLean M.R. Endothelin B receptor mediated contraction in human pulmonary resistance arteries. Br J Pharm. 119:1996;1125-1130.
28. Wagner O.F., Christ G., Wojka J. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 267:1992;16066-16068.
29. Yoshimoto S., Ishizaki Y., Sasaki T., Murota S.I. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke. 22:1991;378-383.
30. Seo B., Oemar B.S., Siebenmann R., Von Segesser L., Luscher T.F. Both ET(A) and ET(B) receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 89:1994;1203-1208.
31. Penny W.F., Weinstein M., Salzman E.W., Ware J.A. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation. 83:1991;1630-1636.
32. Sbarouni E., Bradshaw A., Andreotti F.et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J. 127:1994;607-612.
33. Habib F., Dutka D., Crossman D., Oakley C.M., Cleland J.G.F. Enhanced basal nitric oxide production in heart failure: another failed counter regulatory vasodilator mechanism? Lancet. 344:1994;371-373.
34. Dzau V.J., Packer M., Lilly L.S.et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. New Engl J Med. 310:1984;347-352.
35. Dupuis J., Stewart D.J., Cernacek P., Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 94:1996;1578-1584.
36. Ray S.G., McMurray J.J., Morton J.J., Dargie H.J. Circulating endothelin is not extracted by the pulmonary circulation in man. Chest. 102:1992;1143-1144.
37. Eaton G.M., Bush C.A., VanFossen D.B., Kelley R.E., Cody R.J. Absence of pulmonary endothelin gradient in patients with normal or elevated circulating endothelin. Am J Cardiol. 73:1994;1015-1016.
38. Dupuis J, Gosselin G, Stewart DJ, Tardif J-C, Cernacek P, Dyrda I, Bonan R, Crepeau J. Reduced pulmonary removal of circulating endothelin-1: a new marker of pulmonary hypertension. Circulation 1996;94:I-412 (Abstract).